Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2004;110:2591-2596
Published online before print October 18, 2004, doi: 10.1161/01.CIR.0000145610.64014.E4
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
110/17/2591    most recent
01.CIR.0000145610.64014.E4v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wathen, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wathen, M. S.
Related Collections
Right arrow Ablation/ICD/surgery
Right arrow Arrhythmias, clinical electrophysiology, drugs

(Circulation. 2004;110:2591-2596.)
© 2004 American Heart Association, Inc.


Arrhythmia/Electrophysiology

Prospective Randomized Multicenter Trial of Empirical Antitachycardia Pacing Versus Shocks for Spontaneous Rapid Ventricular Tachycardia in Patients With Implantable Cardioverter-Defibrillators

Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) Trial Results

Mark S. Wathen, MD; Paul J. DeGroot, MS; Michael O. Sweeney, MD; Alice J. Stark, RN, PhD; Mary F. Otterness, MS; Wayne O. Adkisson, MD; Robert C. Canby, MD; Koroush Khalighi, MD; Christian Machado, MD; Donald S. Rubenstein, MD, PhD; Kent J. Volosin, MD, for the PainFREE Rx II Investigators

From the Vanderbilt University Medical Center, Nashville, Tenn (M.S.W.); Medtronic, Inc, Minneapolis, Minn (P.J.D., A.J.S., M.F.O.); Brigham and Women’s Hospital, Boston, Mass (M.O.S.); Portsmouth Cardiology, Portsmouth, Va (W.O.A.); Texas Cardiac Arrhythmia Foundation, Austin, Tex (R.C.C.); Easton Hospital, Easton, Pa (K.K.); Providence Hospital, Southfield, Mich (C.M.); Arrhythmia Consultants, Greenville, SC (D.S.R.); and University of Pennsylvania, Philadelphia (K.J.V.).

Correspondence to Mark Wathen, MD, Vanderbilt Page-Campbell Heart Institute, Vanderbilt University Medical Center, 2220 Pierce, Nashville, TN 37232. E-mail mark.wathen{at}vanderbilt.edu

Received March 25, 2004; revision received June 15, 2004; accepted June 18, 2004.

Background— Successful antitachycardia pacing (ATP) terminates ventricular tachycardia (VT) up to 250 bpm without the need for painful shocks in implantable cardioverter-defibrillator (ICD) patients. Fast VT (FVT) >200 bpm is often treated by shock because of safety concerns, however. This prospective, randomized, multicenter trial compares the safety and utility of empirical ATP with shocks for FVT in a broad ICD population.

Methods and Results— We randomized 634 ICD patients to 2 arms—standardized empirical ATP (n=313) or shock (n=321)—for initial therapy of spontaneous FVT. ICDs were programmed to detect FVT when 18 of 24 intervals were 188 to 250 bpm and 0 of the last 8 intervals were >250 bpm. Initial FVT therapy was ATP (8 pulses, 88% of FVT cycle length) or shock at 10 J above the defibrillation threshold. Syncope and arrhythmic symptoms were collected through patient diaries and interviews. In 11±3 months of follow-up, 431 episodes of FVT occurred in 98 patients, representing 32% of ventricular tachyarrhythmias and 76% of those that would be detected as ventricular fibrillation and shocked with traditional ICD programming. ATP was effective in 229 of 284 episodes in the ATP arm (81%, 72% adjusted). Acceleration, episode duration, syncope, and sudden death were similar between arms. Quality of life, measured with the SF-36, improved in patients with FVT in both arms but more so in the ATP arm.

Conclusions— Compared with shocks, empirical ATP for FVT is highly effective, is equally safe, and improves quality of life. ATP may be the preferred FVT therapy in most ICD patients.


Key Words: defibrillators, implantable • pacing • tachyarrhythmias




This article has been cited by other articles:


Home page
EuropaceHome page
G. Boriani, E. Occhetta, S. Cesario, S. Grossi, M. Marconi, G. Speca, P. Silvestri, M. Biffi, M. Bortnik, C. Martignani, et al.
Contribution of morphology discrimination algorithm for improving rhythm discrimination in slow and fast ventricular tachycardia zones in dual-chamber implantable cardioverter-defibrillators
Europace, June 9, 2008; (2008) eun146v1.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
J. Am. Coll. Cardiol., May 27, 2008; 51(21): e1 - e62.
[Full Text] [PDF]


Home page
CirculationHome page
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
Circulation, May 27, 2008; 117(21): e350 - e408.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. H. Raitt
Implantable Cardioverter-Defibrillator Shocks: A Double-Edged Sword?
J. Am. Coll. Cardiol., April 8, 2008; 51(14): 1366 - 1368.
[Full Text] [PDF]


Home page
Arch Intern MedHome page
R. Passman, H. Subacius, B. Ruo, A. Schaechter, A. Howard, S. F. Sears, and A. Kadish
Implantable Cardioverter Defibrillators and Quality of Life: Results From the Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation Study
Arch Intern Med, November 12, 2007; 167(20): 2226 - 2232.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
S.-C. Yap, J. W. Roos-Hesselink, E. S. Hoendermis, W. Budts, H. W. Vliegen, B. J.M. Mulder, A. P.J. van Dijk, M. J. Schalij, and W. Drenthen
Outcome of implantable cardioverter defibrillators in adults with congenital heart disease: a multi-centre study
Eur. Heart J., August 1, 2007; 28(15): 1854 - 1861.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. Passman and A. Kadish
Sudden Death Prevention With Implantable Devices
Circulation, July 31, 2007; 116(5): 561 - 571.
[Full Text] [PDF]


Home page
CirculationHome page
A. E. Epstein, C. A. Baessler, A. B. Curtis, N.A. M. Estes III, B. J. Gersh, B. Grubb, and L. B. Mitchell
Addendum to "Personal and Public Safety Issues Related to Arrhythmias That May Affect Consciousness: Implications for Regulation and Physician Recommendations: A Medical/ Scientific Statement From the American Heart Association and the North American Society of Pacing and Electrophysiology" Public Safety Issues in Patients With Implantable Defibrillators A Scientific Statement From the American Heart Association and the Heart Rhythm Society
Circulation, March 6, 2007; 115(9): 1170 - 1176.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
A. K. Gehi, D. Mehta, and J. A. Gomes
Evaluation and Management of Patients After Implantable Cardioverter-Defibrillator Shock
JAMA, December 20, 2006; 296(23): 2839 - 2847.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
B. L. Wilkoff, K. T. Ousdigian, L. D. Sterns, Z. J. Wang, R. D. Wilson, J. M. Morgan, and for the EMPIRIC Trial Investigators
A Comparison of Empiric to Physician-Tailored Programming of Implantable Cardioverter-Defibrillators: Results From the Prospective Randomized Multicenter EMPIRIC Trial
J. Am. Coll. Cardiol., July 18, 2006; 48(2): 330 - 339.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. M. Ripplinger, V. I. Krinsky, V. P. Nikolski, and I. R. Efimov
Mechanisms of unpinning and termination of ventricular tachycardia
Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H184 - H192.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. A. Friedman, R. L. McClelland, W. R. Bamlet, H. Acosta, D. Kessler, T. M. Munger, N. G. Kavesh, M. Wood, E. Daoud, A. Massumi, et al.
Dual-Chamber Versus Single-Chamber Detection Enhancements for Implantable Defibrillator Rhythm Diagnosis: The Detect Supraventricular Tachycardia Study
Circulation, June 27, 2006; 113(25): 2871 - 2879.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
Z. Goldberger and R. Lampert
Implantable Cardioverter-Defibrillators: Expanding Indications and Technologies
JAMA, February 15, 2006; 295(7): 809 - 818.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. J. Connolly
Use and Misuse of Surrogate Outcomes in Arrhythmia Trials
Circulation, February 14, 2006; 113(6): 764 - 766.
[Full Text] [PDF]


Home page
CirculationHome page
K. A. Ellenbogen, J. H. Levine, R. D. Berger, J. P. Daubert, S. L. Winters, E. Greenstein, A. Shalaby, A. Schaechter, H. Subacius, A. Kadish, et al.
Are Implantable Cardioverter Defibrillator Shocks a Surrogate for Sudden Cardiac Death in Patients With Nonischemic Cardiomyopathy?
Circulation, February 14, 2006; 113(6): 776 - 782.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
S. J. Connolly, P. Dorian, R. S. Roberts, M. Gent, S. Bailin, E. S. Fain, K. Thorpe, J. Champagne, M. Talajic, B. Coutu, et al.
Comparison of {beta}-Blockers, Amiodarone Plus {beta}-Blockers, or Sotalol for Prevention of Shocks From Implantable Cardioverter Defibrillators: The OPTIC Study: A Randomized Trial
JAMA, January 11, 2006; 295(2): 165 - 171.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
N. Sadoul, R. Mletzko, F. Anselme, R. Bowes, W. Schols, C. Kouakam, G. Casteigneau, R. Luise, N. Iscolo, E. Aliot, et al.
Incidence and Clinical Relevance of Slow Ventricular Tachycardia in Implantable Cardioverter-Defibrillator Recipients: An International Multicenter Prospective Study
Circulation, August 16, 2005; 112(7): 946 - 953.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. E. Buxton, M. O. Sweeney, M. S. Wathen, M. E. Josephson, M. F. Otterness, E. Hogan-Miller, A. J. Stark, P. J. DeGroot, and for the PainFREE Rx II Investigators
QRS Duration Does Not Predict Occurrence of Ventricular Tachyarrhythmias in Patients With Implanted Cardioverter-Defibrillators
J. Am. Coll. Cardiol., July 19, 2005; 46(2): 310 - 316.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
B. Olshansky
Wide QRS, Narrow QRS: What's the Difference?
J. Am. Coll. Cardiol., July 19, 2005; 46(2): 317 - 319.
[Full Text] [PDF]


Home page
CirculationHome page
S. F. Sears Jr, J. B. Shea, and J. B. Conti
How to Respond to an Implantable Cardioverter-Defibrillator Shock
Circulation, June 14, 2005; 111(23): e380 - e382.
[Full Text] [PDF]


Home page
Journal Watch CardiologyHome page
Switch on Antitachycardia Pacing for ICD Patients
Journal Watch Cardiology, January 28, 2005; 2005(128): 4 - 4.
[Full Text]


Home page
CirculationHome page
W. G. Stevenson, B. R. Chaitman, K. A. Ellenbogen, A. E. Epstein, W. L. Gross, D. L. Hayes, S. A. Strickberger, M. O. Sweeney, and for the Subcommittee on Electrocardiography and Ar
Clinical Assessment and Management of Patients With Implanted Cardioverter-Defibrillators Presenting to Nonelectrophysiologists
Circulation, December 21, 2004; 110(25): 3866 - 3869.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
I. R. Hanna and J. J. Langberg
The Shocking Story of Azimilide
Circulation, December 14, 2004; 110(24): 3624 - 3626.
[Full Text] [PDF]